In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans
Copin, R.; Baum, A.; Wloga, E.; Pascal, K. E.; Giordano, S.; Fulton, B. O.; Zhou, A.; Negron, N.; Lanza, K.; Chan, N.; Coppola, A.; Chiu, J.; Ni, M.; Atwal, G. S.; Romero Hernandez, A.; Saotome, K.; Zhou, Y.; Franklin, M. C.; Hooper, A. T.; McCarthy, S.; Hamon, S.; Hamilton, J. D.; Staples, H. M.; Alfson, K.; Carrion, R.; Ali, S.; Norton, T.; Somersan-Karakaya, S.; Sivapalasingam, S.; Herman, G. A.; Weinreich, D. M.; Lipsich, L.; Stahl, N.; Murphy, A. J.; Yancopoulos, G. D.; Kyratsous, C. A.
Show abstract
Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. As rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of minor virus variants in SARS-COV-2 isolates found in COVID-19 patients or identified from preclinical in vitro and in vivo studies. This study demonstrates that a combination of non-competing antibodies, REGEN-COV, not only provides full coverage against current variants of concern/interest but also protects against emergence of new such variants and their potential seeding into the population in a clinical setting.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 96%
- In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2 96%
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 95%
Similar papers in this journal
- Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection 95%
- Antibody escape drives emergence of diverse spike haplotypes resembling variants of concern in persistent SARS-CoV-2 infections 94%
- Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 93%
Similar papers in this journal
- Comprehensive profiling of polyclonal sera targeting a non-enveloped viral capsid 96%
- Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants 96%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.